BVXP vs. ERGO, SLN, PRTC, OXB, HZD, AVCT, FARN, VRP, HVO, and 4BB
Should you be buying Bioventix stock or one of its competitors? The main competitors of Bioventix include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), hVIVO (HVO), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.
Bioventix (LON:BVXP) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.
Ergomed has higher revenue and earnings than Bioventix. Bioventix is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bioventix had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Ergomed. Bioventix's average media sentiment score of 0.67 beat Ergomed's score of 0.00 indicating that Bioventix is being referred to more favorably in the media.
63.0% of Bioventix shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 8.0% of Bioventix shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ergomed has a consensus price target of GBX 1,350, indicating a potential upside of 0.30%. Given Ergomed's higher probable upside, analysts clearly believe Ergomed is more favorable than Bioventix.
Ergomed received 150 more outperform votes than Bioventix when rated by MarketBeat users. Likewise, 75.63% of users gave Ergomed an outperform vote while only 52.87% of users gave Bioventix an outperform vote.
Bioventix has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Bioventix has a net margin of 63.73% compared to Ergomed's net margin of 9.87%. Bioventix's return on equity of 79.14% beat Ergomed's return on equity.
Summary
Ergomed beats Bioventix on 9 of the 16 factors compared between the two stocks.
Get Bioventix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventix Competitors List
Related Companies and Tools
Free BVXP Stock Alerts